FDA grants priority review to AstraZeneca’s sonesitatug vedotin application
The application is supported by Phase III data showing a 42% reduction in risk of death and median overall survival of 10.6 months versus 6.4 months with standard treatment. The BLA covers tumors with CLDN18.2 expression in at least 25% of cells. The drug is also under review in other markets and is being evaluated in earlier-line and additional gastrointestinal cancers.
Citi ranks AstraZeneca as Europe’s strongest big-pharma growth pick
Citi cited 7.3% revenue growth, 22.8% fair-value upside and more than $30 billion in unadjusted peak-sales potential from AstraZeneca’s late-stage pipeline. Its 23.9x P/E and downward earnings revisions from seven analysts were listed as risks. The comparison noted Sanofi’s value and income and Novartis’s earnings consistency but lower upside.
AstraZeneca partners with lupus groups on clinical-trial support
The collaboration includes the pediatric anifrolumab-fnia BLOSSOM trial and early-stage programs in systemic lupus erythematosus and lupus nephritis. These include a CD19/BCMA CAR-T therapy and two T-cell engagers. The partners will provide trial operations, patient and healthcare professional education, peer support, and recruitment services.
Jefferies reiterates buy rating and 17,500p target for AstraZeneca
Jefferies cited confidence that AstraZeneca’s existing pipeline can support its $80 billion annual sales goal by 2030 without major acquisitions. The broker highlighted 12 positive trial readouts with about $10 billion in potential sales, including prospects for Baxfendy and tozorakimab. It also noted reimbursement, patient access and clinical risks, as investors focus on commercialising the medicines.
AstraZeneca reaffirms 2026 guidance after third-quarter results
AstraZeneca reported third-quarter and nine-month results and reaffirmed its 2026 earnings guidance. Third-quarter revenue and core EPS beat estimates, supported by oncology and newer-drug sales. The company’s shares rose, while the article cited its pipeline, clinical setbacks, generic competition and China-related uncertainty among factors investors were weighing.
Klygefa (gefurulimab) is a once-weekly, self-administered subcutaneous C5 inhibitor for adults with AChR antibody-positive generalized myasthenia gravis. Phase III results showed improved daily functioning versus placebo by 26 weeks, with benefits emerging in the first week. The drug offers an alternative to AstraZeneca’s IV C5 inhibitors, Soliris and Ultomiris, but carries a boxed warning for meningococcal infections.
AstraZeneca cuts about 600 US commercial roles in restructuring
The cuts affect about 600 U.S. commercial roles in respiratory and immunology, with some employees potentially reassigned. The three-year program targets $1.5 billion in annualized pretax savings by the end of 2029 and could incur up to $2 billion in costs. AstraZeneca said the program would not reduce global headcount overall, and savings are intended to support drug development.
FDA approves AstraZeneca’s perioperative IMFINZI bladder cancer regimen
The US FDA approved perioperative IMFINZI plus neoadjuvant enfortumab vedotin, followed by adjuvant IMFINZI, for cisplatin-ineligible or cisplatin-refusing adults with muscle-invasive bladder cancer. In the VOLGA Phase III trial, the regimen showed a 49% lower risk of recurrence or other events and a 42% lower risk of death versus the comparator. Grade 3 or 4 adverse events occurred in 64% of treated patients.
AstraZeneca plans to transfer its primary listing to the NYSE
AstraZeneca plans to transfer its primary listing to the New York Stock Exchange in 2026, joining eight other large companies. The move could broaden its U.S. investor base but would not change its business fundamentals. The article said long-term performance remains dependent on clinical and commercial execution across the pipeline, alongside clinical and spending risks.
Omniose will become a wholly owned subsidiary within AstraZeneca’s infectious disease unit. The acquisition adds its single-cell bioconjugation platform for developing bacterial conjugate vaccines and builds on a three-year research collaboration. The technology is designed to simplify vaccine production and support research into vaccines against serious bacterial infections, including drug-resistant bacteria.
Analyst targets for AstraZeneca move in mixed directions
AstraZeneca’s estimated fair value rose from £157.13 to £161.08, reflecting slightly higher revenue growth and profit margin assumptions, partly offset by a lower future P/E. Recent analyst views are mixed: Citi, Barclays and RBC raised targets, while Nordea upgraded to Buy. Deutsche Bank and HSBC remain at Hold, citing valuation and growth risks.
AstraZeneca reportedly offers $10 billion for Rhythm Pharmaceuticals
Reports said AstraZeneca offered $124 per share, or about $10 billion, for Rhythm Pharmaceuticals, a 43% premium to its Tuesday close. Rhythm shares rose 28% Wednesday. The reported acquisition would expand AstraZeneca’s rare-disease portfolio, including treatments for metabolic disorders and severe obesity.
Europe and Japan accept AstraZeneca lung cancer combination filings
AstraZeneca secured regulatory filing acceptance in Europe and Japan for TAGRISSO plus ORPATHYS in MET-driven, EGFR-mutated non-small cell lung cancer, backed by positive Phase III data. The progress adds to broader oncology developments, including EU approval of Enhertu for early HER2-positive breast cancer and positive Sone Ve gastric cancer trial results. Investors await regulatory decisions and label details, including for a US application, as well as safety and uptake data.
AstraZeneca reports nine-month revenue and core EPS growth
AstraZeneca reported nine-month 2026 revenue growth of 7% and core EPS growth of 14%. Management plans a three-year restructuring costing up to $2 billion to generate $1.5 billion in annualized savings for reinvestment in R&D. Tagrisso generated $2.1 billion in quarterly sales, helping offset patent-related headwinds.